As filed with the Securities and Exchange Commission on February 18, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Poseida Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | |
Delaware | | 47-2846548 |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer Identification No.) |
| |
9390 Towne Centre Drive, Suite 200 San Diego, California | | 92121 |
(Address of Principal Executive Offices) | | (Zip Code) |
2020 Equity Incentive Plan
2020 Employee Stock Purchase Plan
2022 Inducement Plan
(Full titles of the plans)
Mark J. Gergen, J.D.
President and Chief Executive Officer
Poseida Therapeutics, Inc.
9390 Towne Centre Drive, Suite 200
San Diego, CA 92121
(858) 779-3100
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Copies to:
| | |
Sean M. Clayton Kenneth J. Krisko Cooley LLP 4401 Eastgate Mall San Diego, California 92121 (858) 550-6000 | | Harry J. Leonhardt, Esq. General Counsel Poseida Therapeutics, Inc. 9390 Towne Centre Drive, Suite 200 San Diego, California 92121 (858) 779-3100 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | |
Large accelerated filer | | ☐ | | Accelerated filer | | ☐ |
| | | |
Non-accelerated filer | | ☒ | | Smaller reporting company | | ☒ |
| | | |
| | | | Emerging growth company | | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐